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Despite decades of research, cerebral malaria remains
one of the most serious complications of Plasmodium
infection and is a significant burden in Sub-Saharan
Africa, where, despite effective antiparasitic treatment,
survivors develop long-term neurological sequelae. Al-
thoughmuch remains to be discovered about the patho-
genesis of cerebral malaria, The American Journal of
Pathology has been seminal in presenting original re-
search from both human and experimental models.
These studies have afforded significant insight into the
mechanism of cerebral damage in this devastating dis-
ease. The present review highlights information
gleaned from these studies, especially in terms of their
contributions to the understanding of cerebral malaria.
(Am J Pathol 2012, 181:1484–1492; http://dx.doi.org/
10.1016/j.ajpath.2012.08.010)
Cerebral malaria (CM) is a severe and potentially fatal
neurological manifestation of infection with Plasmodium
species. P. falciparum, the major causative agent of hu-
man CM, accounts annually for approximately one million
deaths of children in Sub-Saharan Africa alone.1 Despite
effective antimalarial therapy, surviving individuals with
CM may develop long-term neurological deficits,2–9
1484which indicates that elimination of the parasite does not
completely resolve clinical consequences of infection.
Over the past century, The American Journal of Pathology
(AJP) has greatly advanced understanding of the patho-
genesis and pathophysiology of human diseases. This
review focuses on contributions to knowledge of the neu-
rodegenerative disease CM in particular.
Until recently, observation regarding human CM has
been somewhat limited, because it has relied mainly on
examination of postmortem samples, which are not al-
ways accessible.3 This limitation has made animal mod-
els, despite their imperfections, necessary for longitudi-
nal studies of disease pathogenesis.10 Studies with
nonhuman primate models demonstrate several patholog-
ical features similar to those observed in humans, including
sequestration of infected red blood cells (iRBCs) and
vascular damage. However, these studies are difficult to
conduct, because of their considerable ethical and cost
constraints and thus are vastly underutilized.3,11,12 Fur-
thermore, as with all animal models, studies on nonhu-
man primates present a number of reliability issues.3,4,11
Although the mouse model has many of the same limita-
tions, it nonetheless serves as one of the most widely
used animal models for in vivo CM research. Although
some differences undoubtedly exist between human and
murine CM, several studies highlight the range of simi-
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AJP November 2012, Vol. 181, No. 5larities, including perturbations in the integrity of the
blood-brain barrier (BBB), iRBC sequestration to the ce-
rebral microvasculature, microvascular damage, and
persistent cognitive impairment despite successful anti-
malarial therapy. These similarities support the use of the
mouse model to characterize this human disease.10,13
Cerebral microcirculatory disturbances have been im-
plicated as a contributing factor in the pathogenesis of
CM. By a process known as sequestration, P. falciparum-
infected RBCs (PfRBCs) adhere to the brain endothelium
through binding of P. falciparum erythrocyte membrane
protein 1 (PfEMP1), a specific cell-surface ligand ex-
pressed by iRBCs. There is no evidence to date of PfRBC
entry into the brain parenchyma, suggesting that iRBCs
remain in the vascular space when sequestered. PfRBC
sequestration leads to multiple downstream vascular ef-
fects, including increased vasoconstriction, reduced ce-
rebral blood flow, vascular obstruction, and disruption of
BBB integrity.1,14,15
The BBB is a selectively permeable structure respon-
sible for regulating ion and nutrient transport into the
brain. It serves as a key interface between the central
nervous system and the blood, restricting the free flow of
physiological molecules between the bloodstream and
parenchyma. The BBB is composed of specialized en-
dothelial cells (ECs) that line cerebral blood vessels.
These ECs are surrounded by a basal lamina and astro-
cyte end foot processes16 (Figure 1). Tight junctions are
responsible for stitching ECs together for barrier mainte-
nance and integrity, with astrocytes providing additional
structural and physical support.16 Together, these cells
serve as the gatekeepers of the BBB and help the barrier
perform its critical function of maintaining proper brain
homeostasis.
The BBB is a highly complex structure, consisting of
many cell types and possessing multiple functions, and
we have simplified both our description and illustration of
it (Figure 1) for clarity in this review. Perturbations to the
BBB can lead to the passage of potentially harmful sub-
stances into the brain, which may subsequently causedisease. Vascular dysfunction with subsequent BBB
damage is a major feature of CM17–19 (Figure 1) and has
been observed both in pediatric CM and in experimental
models. The mechanisms that mediate this vasculopathy
are not fully characterized. Over the past 20 years, the
damages to the cerebrovasculature and BBB that result
from CM have been delineated in several seminal reports
in AJP, broadening understanding of this aspect of dis-
ease and helping to identify important factors that might
serve as future therapeutic targets. The present review
focuses on the role of cerebrovascular dysfunction in CM,
known mechanisms that mediate this dysfunction, and
possible therapeutic options.
Pediatric CM
Of all populations at risk of acquiring malarial disease,
children 5 years or younger in Sub-Saharan Africa are
most susceptible to developing CM.20 This population is
associated with a staggering 90% of CM-related fatali-
ties.20 CM that occurs in young children, also termed
pediatric CM, is characterized by impaired conscious-
ness, severe anemia, hypoglycemia, fever, and neurolog-
ical sequelae.20 It is clinically defined as the presence of
P. falciparum parasitemia and coma with no other appar-
ent causes of altered consciousness.21
A Vascular Approach to Diagnosing CM:
Retinopathy
The diagnosis of CM is difficult because of the many
nonspecific features characteristic of disease. The pres-
ence of parasite in comatose patients is a poor indicator
of disease, because coma is a known consequence of a
variety of neurological syndromes.22 Over the past 30
years, retinopathy has become one of the best diagnostic
indicators of both pediatric and adult CM,22,23 because
its severity correlates with the hallmark cerebrovascular
Figure 1. Proposed mechanism of vascular
damage and BBB dysfunction in CM. The BBB is
composed of ECs (orange), the basal lamina
(purple), and astrocyte end feet (blue). Left
panel: The vasculopathy in CM is likely a mul-
tifactorial process involving an up-regulation of
the host inflammatory response. Interaction
among PfRBCs, monocytes, and endothelial cells
results in the up-regulation of proinflammatory
cytokines, including TNF- and IL-1, which ac-
tivates the cerebral endothelium.Middle panel:
Additionally, there is recruitment and sequestra-
tion of iRBCs, monocytes, and platelets; this
leads to mechanical occlusion and potentiates
endothelial cell activation, and the up-regulation
of cell adhesion molecules (CAMs) to which
PfRBCs, immune cells, and platelets can adhere
and thus obstruct the blood vessels and disrupt
cerebral blood flow. Right panel: These two
sets of events are thought to lead to BBB dys-
function. Cells of the BBB are damaged and
undergo apoptosis; this allows entry of foreign
materials into the brain parenchyma, creating
hemorrhagic lesions and edema of the brain.PfRBC sequestration and because it helps distinguish
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tures of retinopathy, which include whitening of the retina,
hemorrhage, and abnormality-induced changes in vessel
color, likely result in part from mechanical obstruction
due to PfRBC sequestration and reduced perfusion.23
Funduscopic analysis on Malawian children with CM re-
vealed that papilledema (ie, swelling of the optic disk that
connects the optic nerve to the retina) is another frequent
occurrence during CM and is associated with retinopa-
thy-like characteristics.23 It is not specific to CM, how-
ever, because patients with papilledema do not always
exhibit PfRBC sequestration to the cerebral vascula-
ture.23 This observation is corroborated by the fact that
the case-fatality rate of children with papilledema alone is
higher than that of children with malarial retinopathy and
papilledema, demonstrating that, like coma, papilledema
is a nonspecific outcome of disease, a circumstance that
can lead to misdiagnosis and thus to inappropriate treat-
ment.23 The capacity of retinopathy to accurately diag-
nose CM, along with its high correlation with postmortem
histopathological features of the neurological syndrome,
establishes the importance of performing a funduscopic
examination during evaluation of patients at risk of
disease.
Histopathological Features
Postmortem studies of fatal cases of CM have allowed
researchers to gain a better understanding of this dis-
ease. Dorovini-Zis et al20 demonstrated that, in brains of
Malawian children with CM, the degree of PfRBC se-
questration and microvascular pathology correlated
with the severity of BBB disruption. Areas of fibrinogen
extravasation into the brain parenchyma were ob-
served near areas of thrombus, ring hemorrhage, rup-
tured capillaries, and cerebral blood vessels filled with
PfRBCs20 (Figure 2). Additionally, myelin loss and ax-
onal damage were increased in areas of severe vascular
damage.20 These findings coincided with previous stud-
ies in Vietnamese adults with CM that also demonstrated
axonal injury associated with hemorrhage and demyeli-
nation.24 Furthermore, patients with PfRBC sequestration
and microvascular pathology demonstrated prominent
gliosis, in contrast to those without sequestration and/or
microvascular damage.24
The tight junctions that stitch ECs together are impor-
tant for maintaining BBB integrity. Studies on Malawian
children with CM revealed focal loss of EC tight junction
proteins, such as zonular occludin-1 (ZO-1), occludin,
and vinculin.25 Areas of loss of these tight junctions co-
localized with areas of PfRBC sequestration.25 Loss of
tight junctions likely contributes to the breakdown of the
BBB and the subsequent downstream consequences
that occur during CM.
Vasculopathy
Although the mechanisms of cerebrovascular dysfunc-
tion in CM remain incompletely characterized, several
factors have been implicated, including increased levelsof the vasoactive peptide endothelin-1 (ET-1), as well as
the proinflammatory cytokines tumor necrosis factor-
(TNF-) and interferon- (IFN-).1,26,27 Hyperinflamma-
tion has been observed in a murine model of CM, char-
acterized by systemic activation of several cell types (ie,
CD4 and CD8 T cells, macrophages, and plate-
lets).28–31 Murine CM results from infection of mice with
the mouse malarial strain P. berghei-ANKA (PbA); this
model is here referred to as experimental CM (ECM).
Enhanced expression of ET-1, TNF-, and IFN- acti-
vates the endothelium, inducing increased recruitment of
iRBCs, leukocytes, and platelets, as well as up-regulation
of several endothelial cell adhesion molecules (CAMs),
including intracellular adhesion molecule-1 (ICAM-1),
vascular adhesion molecule-1 (VCAM-1), and E-selectin
(CD62E).1,32,33
Cell Adhesion Molecules
Up-regulation of CAMs increases the potential for binding
of recruited cells to the endothelial membrane, an event
that results in cerebral microvascular sequestration.32,34
In this regard, ICAM-1 (CD54) and CD36 are two major
binding partners for the PfEMP1 protein on PfRBCs and
thus contribute to PfRBC sequestration. Enhanced PfRBC
sequestration leads to vascular obstruction, hypoperfu-
sion, and hypo-oxygenation, which are hallmark features
of such characteristic CM conditions as acidosis, hyp-
oxia, and ischemia.30,32,34,35 Sequestration results in
both damage to and apoptosis of ECs and renders the
BBB susceptible to dysfunction, thus increasing the pos-
sibility of vascular leakage into the brain tissue.32 Such
vascular leakage likely contributes to the neuronal dam-
age and brain edema observed during disease.32 En-
Figure 2. Patterns of BBB compromise in fatal pediatric CM. A and B: In
young children with CM, fibrinogen leakage (arrows), signaling BBB break-
down, is observed immediately adjacent to capillaries densely packed with
PfRBCs and leukocyte infiltration (arrowheads). C and D: Fibrinogen leak-
age (arrows) is also seen juxtaposed to a thrombosed vessel (C, arrow-
head) and in ring hemorrhages in the white matter (D). Thrombosis and
hemorrhage are two prominent features of CM. Reprinted from Dorovini-Zis
et al20 with permission of Elsevier.hanced up-regulation of CAMs also increases the poten-
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endothelial surface, including leukocytes and platelets.
Sequestration leads to the uncontrolled release of micro-
particles and inflammatory cytokines from ECs. This dys-
regulated inflammatory cascade further exacerbates
BBB damage and permeability, increasing the likelihood
of the hemorrhage characteristic of disease. In some
cases of severe ECM, parasite-induced EC damage re-
sulted in complete vessel collapse.14
Significant increases in both CAM expression and
TNF- and IL-1 levels have been observed in postmor-
tem brains of children with CM, especially in the cerebel-
lum.36 Because the cerebellum is important for motor
coordination and for the learning of motor skills, damage
to this brain region may contribute to the subsequent
neurocognitive and motor coordination deficits com-
monly observed in children with CM.
Tripathi et al37 found that exposure of human brain
microvascular ECs to PfRBCs induced the expression of
ICAM-1. This is consistent with the postmortem observa-
tions of Turner et al,38 that iRBCs sequestered in the
vasculature colocalized with ICAM-1. The importance of
ICAM-1 in the development of CM is well established. A
study by Favre et al39 showed that ICAM-1-deficient mice
were protected from CM. Although PbA-infected wild-
type mice survived to 6 to 8 days after infection, ICAM-
1-deficient mice demonstrated a resistance phenotype,
surviving more than 15 days after infection.39 Further-
more, ICAM-1-deficient mice exhibited decreased serum
TNF- levels, no apparent BBB breakdown, and no mac-
rophage sequestration in the cerebral blood vessels, in
contrast to wild-type infected mice.39 These findings
demonstrate that ICAM-1 up-regulation during CM may
be associated with macrophage and iRBC entrapment,
as well as with immune dysregulation.
Angiopoietin-Tie-2 Signaling
CM has been shown to result in dysregulation of other
elements of the cerebral vasculature, including the an-
giopoietin-Tie-2 system, a key regulator of EC function
and vascular integrity.33 Under normal conditions, angio-
poietin-1 (Ang-1) regulates the survival and activation of
ECs through interactions with the EC receptor Tie-2,
whereas angiopoietin-2 (Ang-2) opposes the effects of
Ang-1.33 The antagonistic properties of Ang-2 sensitizes
the endothelium to inflammation, which then contributes
to increased expression of ICAM-1, to which PfRBCs and
immune cells can adhere. Interestingly, in cases of se-
vere malaria, low levels of Ang-1 and high levels of Ang-2
have been observed to correlate with the severity of ma-
larial infection.33,40–42 Conroy et al33 examined brains of
children with CM to determine whether a correlation ex-
ists between peripheral blood plasma levels of Ang-1,
Ang-2, and the soluble form of Tie-2 (sTie-2) and retinop-
athy and mortality. Increased levels of Ang-2 and sTie-2,
which binds angiopoietins to regulate their function, were
associated with fatal cases; these molecules thus have
potential as key biomarkers of disease.33 Retinopathy-
positive CM children exhibited decreased Ang-1 and in-
creased Ang-2 and sTie-2, compared with retinopathy-negative children with malaria.33 Ang-2 and sTie-2 levels
correlated with the severity of retinopathy in children with
CM.33 Interestingly, in retinopathy-positive CM children,
Ang-2 was significantly higher in fatal cases.33
Inflammation
A hyperactive immune response is one of the major con-
tributors to CM vasculopathy. Dysregulation of TNF- is
most commonly associated with disease.43 Circulating
levels of this inflammatory cytokine are significantly
higher in ECM mice, compared with mice that do not
develop the neurological syndrome.43 TNF- is thought
to induce activation of ECs, thereby up-regulating ex-
pression of several CAMs, including ICAM-1 (CD54),
CD36, P-selectin (CD62P), and VCAM-1 (CD106).43,44
LMP-420, a transcriptional inhibitor of TNF-, has been
shown to reduce TNF--mediated EC activation, ICAM-1
and VCAM-1 up-regulation, and PfRBC cytoadherence in
an in vitro CM model.45 This molecule also inhibits lym-
photoxin- (LT-; alias TNF-), a TNF receptor 2 (TNFR2)
ligand that is up-regulated in the sera of human malaria
patients, as well as in the brains of mice with ECM.43,45
Interestingly, studies showed that LT--deficient mice
were protected from developing ECM, but blocking
TNF- alone did not protect mice from developing dis-
ease. These findings point to a more specific role for LT-
in pathogenesis.43 PbA-infected mice lacking LT- dem-
onstrated no perivascular hemorrhage; these mice regu-
lated ICAM-1 expression and exhibited resistance to
ECM-induced early death.46 LT- binds TNFR2 on ECs to
induce its downstream inflammatory effects, as demon-
strated by the observation that blocking this receptor also
prevented mice from developing ECM.43 Additionally, the
soluble form of TNFR2 is elevated in both human and
murine CM; however, the importance of this for disease
pathology is unclear.10,43
Another inflammatory mediator associated with CM is
platelet-activating factor (PAF). PAF is an important factor
in leukocyte recruitment and activation, cytokine/chemo-
kine release, and vascular permeability.47,48 PAF signals
through its cognate receptor, platelet-activating factor
receptor (PAFR), to perform its functions. In a recent
study by Teixeira and colleagues,47 PbA-infected mice
lacking PAFR exhibited survival benefits, with reduced
cerebrovascular occlusion and brain hemorrhage. ECM
mice lacking PAFR also demonstrated a decrease in cell
apoptosis, BBB breakdown, and inflammation.
Beyond Inflammation: Cerebral Microcirculation
and Vasomodulatory Agents
In recent years, it has become apparent that alteration of
the cerebral microcirculation is an important factor in the
pathogenesis of CM. The cerebral microvasculature is
essential for central nervous system homeostasis and
normal brain activity. Breach of the BBB during CM, once
thought to be primarily a manifestation of ECM, is increas-
ingly recognized as a contributor to the development of
human CM.20,49 During disease, sequestered PfRBCs
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ing permeability, endothelial activation, and vascular ob-
struction and thus contributing to cerebral microcircula-
tory alterations.17,18,50 Nonetheless, the role of vascular
dysfunction in CM remains poorly understood, and this
paucity of knowledge hampers development of adjunc-
tive therapies targeting vasculopathy.
Endothelin-1
Studies of murine ECM demonstrate elevated levels of
ET-1, a powerful vasoconstrictor, in whole brains of PbA-
infected mice.26 These findings correlate with decreased
cerebral blood flow and immunopathology.15,26 En-
hanced expression of ET-1 is known to result in activation
of the endothelium, thereby up-regulating CAM expres-
sion,26 which suggests that ET-1 may be involved in
potentiating the increased recruitment of iRBCs, leuko-
cytes, and platelets to the cerebral vasculature.51 These
events may enhance sequestration, leading to vascular
obstruction, hypoperfusion and hypo-oxygenation, and
eventually ischemia.
NO and Vascular Dysfunction
The role of nitric oxide (NO) during CM development
has been a matter of great debate. Although NO has
been primarily associated with protection against CM,
studies reveal that it may also contribute to pathogen-
esis. Elevated levels of NO can result in weight loss,
interfere with neurotransmission, and contribute to in-
tracranial pressure through vasodilatory effects.52
Conversely, depleted levels of the agent have been
linked to endothelial dysfunction and damage in
CM.53,54 Several factors may contribute to NO deple-
tion during disease, including both hypoargininemia
(leading to decreased NO production by central ner-
vous system NO synthases) and the NO-scavenging
activity of cell-free hemoglobin, which results from
iRBC destruction.35,53 Through a mechanism similar to
that underlying the effects of ET-1, TNF-, and IFN- on
CM pathogenesis, decreased NO is thought to mediate
vascular obstruction and reduction of cerebral blood
flow via endothelial activation and increased leukocyte
and platelet sequestration.27,53,55–61 Hemorrhage from
vessel collapse has also been associated with deficits
in NO.1,14,27,53
Carvalho and colleagues27 demonstrated that treat-
ment of PbA-infected mice with NO reduced endothelial
activation and the ensuing up-regulation of ICAM-1,
VCAM-1, and P-selectin. Reduced up-regulation of these
cell-surface proteins correlated with reduced sequestra-
tion of leukocytes and platelets to the brain endothelial
lining, which subsequently induced vasodilation, result-
ing in improved microvascular blood flow and decreased
potential for vascular leakage and subsequent hemor-
rhage.27,53 In Asian adult CM patients, as well as in
PbA-infected mice, treatment with exogenous arginine
has been shown to increase NO production and subse-
quently ameliorate endothelial function, thus reducing
CM-associated BBB rupture.53,54,62,63Neuroimaging
Neuroimaging has become an important tool in elucidat-
ing the underlying mechanisms of CM. Various brain
scanning modalities have been used to enhance the clin-
ical characterizations of disease, including magnetic res-
onance imaging (MRI), computerized tomography (CT),
positron emission tomography (PET), and intravital mi-
croscopy. Imaging studies have allowed malaria re-
searchers to look beyond postmortem samples and to
perform longitudinal studies, thus improving understand-
ing of the development of the neurological syndrome.
Visualization Through MRI and CT
MRI is a powerful diagnostic tool for monitoring and un-
derstanding key features involved in the progression of
central nervous system diseases such as CM. Using this
noninvasive imaging device in ECM models, researchers
have demonstrated that ischemia and edema are com-
plications associated with murine CM.19 For example,
MRI studies have demonstrated cranial nerve damage as
an initial lesion of ECM, depicting areas of axonal dam-
age and swelling of the trigeminal and optic nerves.19
MRI also demonstrated decreased cerebral blood flow,
as well as neuronal and axonal injury, in mice infected
with PbA.15 Such applications of MRI allow for more thor-
ough longitudinal studies, which are difficult to achieve
with humans.
Imaging techniques have been used in the setting of
human CM. For example, one group performed head CT
scanning on children diagnosed with CM.22 Images ob-
tained from children with prolonged coma demonstrated
large vessel infarcts with diffuse cerebral swelling in the
brainstem, whereas survivors of CM with neurological
sequelae demonstrated areas of atrophy corresponding
to regions affected by seizures.22 Recent evidence indi-
cates that retinopathy-positive children with CM have
markedly increased cerebral volume, with abnormal T2
signal intensity in the basal ganglia, white matter, and
corpus callosum, compared to retinopathy-negative chil-
dren with CM.64 These findings highlight the advantage
of incorporating these imaging modalities in the study of
the pathogenesis of this neurodegenerative syndrome.
FDG-PET: Imaging Brain Metabolism
Perhaps as a result of the cerebral microvascular disrup-
tions associated with CM, cerebral metabolic activity is
found to be altered as disease progresses. Fluorodeoxy-
glucose positron emission tomography (FDG-PET) is a
noninvasive imaging tool used to quantify metabolic ac-
tivity in various organs, including the brain. FDG is a
glucose analog that is taken up by cells but is not me-
tabolized, allowing researchers to visualize its uptake in
vivo as disease progresses. Sugiyama et al65 demon-
strated decreased cerebral metabolic activity in a non-
human primate model of ECM by FDG-PET. They ob-
served a diffuse and heterogeneous reduction of
metabolic activity in the frontal and temporal lobes before
any evidence of neuropathological findings, suggesting
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mal damage in primate ECM models.65 Diffuse reduction
in activity may result from impaired circulation due to
sequestration.65
Intravital Microscopy
Intravital microscopy enables studies to go beyond
brain histochemical analyses, viewing the live brain
through a cranial window. This technique allows for
long-term imaging of a single area in the brain for
comparison of histopathological alterations and behav-
ioral performances with microvascular changes.66 In-
travital microscopy has emerged as an important tool
in determining the underlying pathological features
contributing to ECM. Carvalho and colleagues used
this modality to explore the cerebral microvasculature
during disease progression (Figure 3).14,27,53 One of
Figure 3. The murine model ECM is associated with vascular collapse. Mice
were infected with P. berghei-ANKA strain. A–C: In mice with ECM, collapse
of a major vessel and branches (arrows, B) is observed on day 6 of infection.
D–F: There is collapse of two branches (arrow, E) of a vessel and micro-
hemorrhages (circles, F). Vessel collapse occurred between two observa-
tions on the same day (day 6 of infection); the mouse developed clinical CM
during the interval between observations. G–I: Collapse of virtually the entire
vascular network is observed on day 6 of infection. J–L: Collapse of the
vascular network on day 6 after a major hemorrhage (arrows, J and K) on
days 4 and 5 of infection. Reprinted from Cabrales et al14 with permission of
Elsevier.their intravital microscopic studies revealed increasedleukocyte adhesion and rolling in brains of PbA-in-
fected mice, which resulted in reduced cerebral blood
flow, arteriole diameter, and RBC velocity.14
Intravital microcopy was used to visualize the micro-
vasculature after administration of a calcium channel
blocker nimodipine to PbA-infected mice. Nimodipine
not only reversed the cerebral vascular disturbances
during infection, but also improved survival and motor
coordination.14 Intravital microscopy was also used to
demonstrate the benefits of treating ECM with exoge-
nous NO, which reduced leukocyte and platelet adher-
ence and also reduced BBB permeability.27,53 The im-
portance of intravital imaging is evident in its ability to
visualize in vivo brain events that will contribute to a
greater understanding of microcirculatory hemody-
namics and vascular pathology during the pathogene-
sis of CM. This tool can also allow researchers to
visually assess the function of specific vascular genes
through knock-out studies, and to determine the effi-
cacy of various therapeutic treatments.
Looking Forward
Bridging the Gap: Human Disease versus
Experimental Models
Despite controversy regarding their validity, animal
models have greatly improved understanding of the
disease process of CM and its pathogenesis. For in-
stance, findings from mouse studies demonstrating the
diagnostic value of MRI, and its potential for therapeu-
tic applications, have been an important rationale for
the increased use of MRI in patients with cerebral
malaria in endemic areas.64 In addition, recent inves-
tigations in Ghanaian children have deepened under-
standing of the role of endothelial progenitor cells in
the maintenance of the cerebrovasculature during in-
fection, as well as of the involvement of these cells in
the development of CM. These findings corroborate
evidence from animal models delineating the role of
these cells in studies involving endothelial cell injury.67
Although only a few other recent investigations dem-
onstrate correlation between experimental models and
human CM,18,20,24,49 such studies underscore the
need for further research linking the two, as well as the
need for collaborations between those who investigate
human CM and those who study experimental models,
to further understanding of the disease and to derive
adjuvant therapies that may be neuroprotective.
Adjunctive Therapies: Repairing the
Cerebrovasculature
Although early adjuvant therapy is the subject of ongoing
debate,12 agents targeting the endothelium have been
established as neuroprotective in animal models and
may also prove to be important both in decreasing mor-
tality with CM and decreasing morbidity in survivors who
experience persistent neurocognitive impairment after
the disease. In this regard, compounds that function in
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hold promise for both mechanistic discoveries and ther-
apeutic options for the treatment of CM. The peroxisome
proliferator-activated receptor- (PPAR-) agonist rosigli-
tazone, the calcium-channel blocker nimodipine, and
erythropoietin fall into this category of cerebrovascular
modulators, and preliminary evidence demonstrates that
these agents decrease mortality due to ECM.1,68,69
These compounds mediate their effects primarily by in-
creasing levels of progenitor ECs and inducing their dif-
ferentiation.1,70 Because damage to the endothelium is
critical to the development of CM, restoring normal levels
of ECs could ameliorate or prevent negative outcomes of
this neurodegenerative disease.
Calcium-Channel Blockade
Mice with ECM that received both the calcium-channel
blocker nimodipine and the antimalarial agent artemether
showed a marked improvement in vascular function,
characterized by increased vasodilation/vasorelaxation
and enhanced cerebral blood flow.1,14 This demonstrates
a possible role for dysregulated calcium flux in the patho-
genesis of CM. Combination treatment with artemether
and the calcium-channel blocker also improved neuro-
cognitive function in mice with disease.1,14
Peroxisome Proliferator-Activated Receptors
The balance between inflammation and immunosup-
pression is critical to a successful defense against infec-
tious agents. Given that CM is a syndrome characterized
by hyperinflammation, regulating the host immune re-
sponse may ameliorate disease pathology. PPARs have
several immunoregulatory properties, including suppres-
sion of both the expression of specific CAMs and Toll-like
receptors and the secretion of various chemokines;
PPARs thus hold promise for reversing the deleterious
effects of CM-associated inflammation.71,72 Although
knowledge of the role of PPARs in CM is limited, agonists
have been shown to ameliorate many of the features
typically found during disease in ECM by, for example,
regulating CAM activation, the secretion of inflammatory
cytokines, and the recruitment of leukocytes to sites of
inflammation.71 PPARs also possess neuroprotective ca-
pabilities, an exciting characteristic in the face of the
neuronal damage and neurological deficits that normally
result from CM.71
Targeting Hypoxia
Oxygen is essential for normal cellular function, homeo-
stasis and metabolism.73,74 Inadequate oxygenation of tis-
sues can lead to hypoxia during CM.73 Therapies that re-
verse hypoxia during disease may thus be beneficial to
patients. Oxygen treatment of mice with ECM has been
shown to significantly reduce disease pathology by improv-
ing survival and BBB integrity and by reducing parasitemia,
leukocyte sequestration, and mRNA levels of TNF- and
IFN-.48,73,75 Grau and colleagues73 demonstrated that
treatment of CM-susceptible mice with the hypoxia-respon-sive hormone erythropoietin (EPO) both reduced the num-
ber of hypoxia-positive central nervous system cells and
restored body temperature to normal levels. In the same
report, they also corroborated a previous finding on the
survival benefits of EPO in ECM.73,76 Additionally, EPO has
been shown to decrease neuronal apoptosis and regulate
expression of TNF-, IFN-, and IL-1 in ECM, thus dem-
onstrating a simultaneous neuroprotective and immuno-
regulatory role, which further establishes EPO as a possible
vasoregulatory therapeutic for CM.76
Endothelin-1
A recent report by Dai et al77 demonstrated the role of
endothelin on the vasculopathy of cerebral malaria via
actions through the endothelin receptor type A (ETA).
These investigators demonstrated that blockade of the
ETA receptor not only significantly reduced hemorrhage
in the brain, it seemed also to synergistically result in a
survival benefit when used as an adjunct to artemisinin.
This finding highlights the fact that aborting activation of
the endothelium and properly maintaining endothelial ho-
meostasis are vital in preventing downstream vascular
and BBB damage in ECM.
Conclusions
Over the decades, AJP has been an important contribu-
tor in advancing understanding of CM pathogenesis, es-
pecially in the area of vasculopathy. We celebrate the
contributions of individuals such as Terrie E. Taylor, Kat-
erina Dorovini-Zis, Leonardo José de Moura Carvalho, Isa-
belle M. Medana, Georges E.R. Grau, and countless others
to the Journal. Through their work and that of others, we now
have a greater appreciation of the pathogenesis of CM in
both humans and mice. Dorovini-Zis, Taylor, and col-
leagues20 provided a comprehensive postmortem analysis
of brains from Malawian children with CM, which demon-
strated the correlation between PfRBC sequestration to the
cerebrovasculature and such pathological consequences
as BBB disruption, hemorrhage, damage to neuronal ax-
ons, demyelination, vascular thrombosis, andmonocyte ac-
cumulation. Carvalho and colleagues14 characterized the
damage to the cerebrovascular system which occurs in
ECM, specifically emphasizing the constricting effects on
vessel diameter and the reduction in blood flow which re-
sults, in part, from sequestration of accumulating leuko-
cytes. Their work not only elucidated potential vascular
components to target therapeutically, such as calcium flux,
but also highlighted the value of intravital microscopy as an
imaging tool to study this neurological syndrome.14 Grau
and colleagues73 further established hypoxia as one of the
major complications which results from ECM and illumi-
nated the hypoxia-reversing hormone EPO as another pos-
sible therapeutic with which to treat disease. Publication in
AJP of work by these prominent scientists, and by many
others, exemplifies the role of the Journal as amajor conduit
for changing concepts of the pathogenesis of CM. Such
contributions will, one can reasonably hope, eventually lead
to improved therapy.
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